The Emerging Role of Dickkopf-1 in Bone Biology: Is It the Main Switch Controlling Bone and Joint Remodeling?

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 2, 2011, Pages 170-177

  Daoussis, Dimitrios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Ankylosing spondylitis; Bone; Bone mass; Dickkopf 1; DKK 1; Joint remodeling; Osteoarthritis; Osteoporosis; Rheumatoid arthritis; Wnt

Indexed keywords

BETA CATENIN; CORTICOSTERONE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; ETANERCEPT; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STEROID; TUMOR NECROSIS FACTOR; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BONE EROSION; BONE MASS; BONE METASTASIS; BONE REMODELING; CORTICOSTEROID INDUCED OSTEOPOROSIS; HUMAN; JOINT FUNCTION; JOINT REMODELING; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPHYTE; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ANIMALS; BONE AND BONES; BONE DISEASES; BONE REMODELING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 80755189018     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.01.006     Document Type: Article

References (53)

1. Kawano Y., Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627-2634.
2. Daoussis D., Andonopoulos A.P., Liossis S.N. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 2010, 39:369-383.
3. Johnson M.L., Kamel M.A. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007, 19:376-382.
4. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209.
5. Miller J.R. The Wnts. Genome Biol 2002, 3. REVIEWS3001.
6. Goldring S.R., Goldring M.B. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007, 13:133-134.
7. Ai M., Heeger S., Bartels C.F., Schelling D.K. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 2005, 77:741-753.
8. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
9. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
10. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
11. Baron R., Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
12. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
13. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
14. MacDonald B.T., Joiner D.M., Oyserman S.M., Sharma P., Goldstein S.A., He X., et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007, 41:331-339.
15. Morvan F., Boulukos K., Clement-Lacroix P., Roman R.S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
16. Wang F.S., Ko J.Y., Lin C.L., Wu H.L., Ke H.J., Tai P.J. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007, 40:485-492.
17. Heiland G.R., Zwerina K., Baum W., Kireva T., Distler J.H., Grisanti M., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, [Epub ahead of print].
18. Chang D.J., Ji C., Kim K.K., Casinghino S., McCarthy T.L., Centrella M. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 1998, 273:4892-4896.
19. Ohnaka K., Tanabe M., Kawate H., Nawata H., Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005, 329:177-181.
20. Mak W., Shao X., Dunstan C.R., Seibel M.J., Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009, 85:538-545.
21. Wang F.S., Ko J.Y., Yeh D.W., Ke H.C., Wu H.L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008, 149:1793-1801.
22. Yao W., Cheng Z., Pham A., Busse C., Zimmermann E.A., Ritchie R.O., et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008, 58:3485-3497.
23. Glantschnig H., Hampton R.A., Lu P., Zhao J.Z., Vitelli S., Huang L., et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 2010, [Epub ahead of print].
24. Anastasilakis A.D., Polyzos S.A., Avramidis A., Toulis K.A., Papatheodorou A., Terpos E. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf) 2010, 72:752-757.
25. Daoussis D., Liossis S.N., Solomou E.E., Tsanaktsi A., Bounia K., Karampetsou M., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
26. Uderhardt S., Diarra D., Katzenbeisser J., David J.P., Zwerina J., Richards W.G., et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010, 69:592-597.
27. Voorzanger-Rousselot N., Ben Tabassi N.C., Garnero P. Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis. Ann Rheum Dis 2009, 68:1513-1514.
28. Garnero P., Tabassi N.C., Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008, 35:2313-2315.
29. Liu Y.Y., Long L., Wang S.Y., Guo J.P., Ye H., Cui L.F., et al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl) 2010, 123:1407-1412.
30. Dalbeth N., Pool B., Smith T., Callon K.E., Lobo M., Taylor W.J., et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010, 12:R164.
31. Weng L.H., Wang C.J., Ko J.Y., Sun Y.C., Wang F.S. Control of Dkk-1 ameliorates chondrocyte apoptosis, cartilage destruction, and subchondral bone deterioration in osteoarthritic knees. Arthritis Rheum 2010, 62:1393-1402.
32. Weng L.H., Wang C.J., Ko J.Y., Sun Y.C., Su Y.S., Wang F.S. Inflammation induction of Dickkopf-1 mediates chondrocyte apoptosis in osteoarthritic joint. Osteoarthritis Cartilage 2009, 17:933-943.
33. Lane N.E., Nevitt M.C., Lui L.Y., de Leon P., Corr M. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007, 56:3319-3325.
34. Reid I.R., Nicholson G.C., Weinstein R.S., Hosking D.J., Cundy T., Kotowicz M.A., et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996, 101:341-348.
35. Naot D., Bava U., Matthews B., Callon K.E., Gamble G.D., Black M., et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007, 22:298-309.
36. Marshall M.J., Evans S.F., Sharp C.A., Powell D.E., McCarthy H.S., Davie M.W. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 2009, 42:965-969.
37. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
38. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
39. Kaiser M., Mieth M., Liebisch P., Oberlander R., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
40. Heider U., Kaiser M., Mieth M., Lamottke B., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009, 82:31-38.
41. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583.
42. Li Z.G., Yang J., Vazquez E.S., Rose D., Vakar-Lopez F., Mathew P., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 2008, 27:596-603.
43. Hall C.L., Bafico A., Dai J., Aaronson S.A., Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65:7554-7560.
44. Hall C.L., Daignault S.D., Shah R.B., Pienta K.J., Keller E.T. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008, 68:1396-1404.
45. Hall C.L., Kang S., MacDougald O.A., Keller E.T. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006, 97:661-672.
46. Karim R., Tse G., Putti T., Scolyer R., Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004, 36:120-128.
47. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 2005, 102:17406-17411.
48. Lories R.J., Derese I., de Bari C., Luyten F.P. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007, 56:489-497.
49. van der H.D., Landewe R., Baraliakos X., Houben H., van Tubergen A., Williamson P., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063-3070.
50. van der H.D., Landewe R., Einstein S., Ory P., Vosse D., Ni L., et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331.
51. Sieper J., Appel H., Braun J., Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008, 58:649-656.
52. Maksymowych W.P., Chiowchanwisawakit P., Clare T., Pedersen S.J., Ostergaard M., Lambert R.G. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009, 60:93-102.
53. Maksymowych W.P. What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?. Arthritis Res Ther 2009, 11:101.